3837 related articles for article (PubMed ID: 7503636)
1. Comparative evaluation of toxicity and antitumor activity of original and reproduced anthracycline drugs.
Kuśnierczyk H; Radzikowski C; Górecki P; Cichocka K
Arch Immunol Ther Exp (Warsz); 1994; 42(1):51-62. PubMed ID: 7503636
[TBL] [Abstract][Full Text] [Related]
2. Experimental antitumor activity and toxicity of the selected triazolo- and imidazoacridinones.
Kuśnierczyk H; Chołody WM; Paradziej-Lukowicz J; Radzikowski C; Konopa J
Arch Immunol Ther Exp (Warsz); 1994; 42(5-6):415-23. PubMed ID: 8572901
[TBL] [Abstract][Full Text] [Related]
3. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
[TBL] [Abstract][Full Text] [Related]
4. Influence of the structure of new anthracycline antibiotics on their biological properties.
Wasowska M; Oszczapowicz I; Wietrzyk J; Opolski A; Madej J; Dzimira S; Oszczapowicz J
Anticancer Res; 2005; 25(3B):2043-8. PubMed ID: 16158943
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties.
Zou Y; Ling YH; Van NT; Priebe W; Perez-Soler R
Cancer Res; 1994 Mar; 54(6):1479-84. PubMed ID: 8137251
[TBL] [Abstract][Full Text] [Related]
6. [Models of preclinical studies of anthracyclines].
Fizames C
Pathol Biol (Paris); 1987 Jan; 35(1):41-8. PubMed ID: 3550611
[TBL] [Abstract][Full Text] [Related]
7. [The antitumor activity of liposomal aclarubicin in vitro and in vivo].
Viadro MM; Navashin SM
Biull Eksp Biol Med; 1991 Nov; 112(11):523-5. PubMed ID: 1810495
[TBL] [Abstract][Full Text] [Related]
8. [Effects of anthracycline drugs (aclarubicin, daunorubicin, doxorubicin, epirubicin, pirarubicin) on mouse acute toxicity and rat liver microsomal lipid peroxidation].
Shinozawa S; Gomita Y; Araki Y
Gan To Kagaku Ryoho; 1992 Jun; 19(6):805-9. PubMed ID: 1605657
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a review.
Goldin A; Venditti JM; Geran R
Invest New Drugs; 1985; 3(1):3-21. PubMed ID: 3886588
[TBL] [Abstract][Full Text] [Related]
10. Biological evaluation of mitoxantrone dihydrochloride synthesized by a new method. I. Acute toxicity and antitumor activity in mouse transplantable tumor systems.
Matuszyk J; Kuśnierczyk H; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1989; 37(1-2):77-88. PubMed ID: 2619512
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity and toxicity in animals of RR-150 (7-cysteaminomitosane), a new mitomycin derivative.
Bradner WT; Rose WC; Schurig JE; Schlein A; Huftalen JB
Cancer Res; 1984 Dec; 44(12 Pt 1):5619-23. PubMed ID: 6437670
[TBL] [Abstract][Full Text] [Related]
12. [The cross resistance to cytostatics of leukemia P388 cells with induced resistance to doxorubicin].
Donenko FV; Sitdikova SM; Kabieva AO
Biull Eksp Biol Med; 1993 Sep; 116(9):309-11. PubMed ID: 8118011
[TBL] [Abstract][Full Text] [Related]
13. Activity of menogaril against various malignant lymphoma cell lines and a human lymphoma xenograft in mice.
Yoshida M; Fujioka A; Nakano K; Yuasa C; Toko T; Takeda S; Unemi N
Anticancer Res; 1996; 16(5A):2875-9. PubMed ID: 8917401
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of antitumor activity of KW-2189, a novel water-soluble derivative of duocarmycin, against murine and human tumors.
Kobayashi E; Okamoto A; Asada M; Okabe M; Nagamura S; Asai A; Saito H; Gomi K; Hirata T
Cancer Res; 1994 May; 54(9):2404-10. PubMed ID: 8162588
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, antitumor activity, and cardiac toxicity of new 4-demethoxyanthracyclines.
Penco S; Casazza AM; Franchi G; Barbieri B; Bellini O; Podestà A; Savi G; Pratesi G; Geroni C; Di Marco A; Arcamone F
Cancer Treat Rep; 1983; 67(7-8):665-73. PubMed ID: 6575865
[TBL] [Abstract][Full Text] [Related]
16. Experimental evaluation of anthracycline analogs.
Casazza AM
Cancer Treat Rep; 1979 May; 63(5):835-44. PubMed ID: 455325
[TBL] [Abstract][Full Text] [Related]
17. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity evaluation of bromine-substituted analogues of ifosfamide. I. Stereodifferentiation of biological effects and selection of the most potent compounds.
Glazman-Kuśnierczyk H; Matuszyk J; Radzikowski C
Immunopharmacol Immunotoxicol; 1992; 14(4):883-911. PubMed ID: 1294626
[TBL] [Abstract][Full Text] [Related]
19. Are syngeneic mouse tumor models still valuable experimental models in the field of anti-cancer drug discovery?
Darro F; Decaestecker C; Gaussin JF; Mortier S; Van Ginckel R; Kiss R
Int J Oncol; 2005 Sep; 27(3):607-16. PubMed ID: 16077908
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of epirubicin cytotoxicity by cycloheximide.
Furusawa S; Nakano S; Wada M; Chiba H; Takayanagi M; Takayanagi Y; Sasaki K
Res Commun Mol Pathol Pharmacol; 1996 Feb; 91(2):245-8. PubMed ID: 8832916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
